Implantable Cardioverter Defibrillator and Cardiac Resynchronization Treatment in People with Type 2 Diabetes: a Comparison with Age- and Sex Matched Controls from the General Population

Overview

Journal Cardiovasc Diabetol

Publisher Biomed Central

Specialties Cardiology & Vascular Diseases
Endocrinology

Date 2024 Jan 6

PMID 38184588

Authors

Elina Rautio

Fredrik Gadler

Soffia Gudbjornsdottir

Stefan Franzen

Lars Ryden

Gianluigi Savarese

Ann-Marie Svensson

Linda G Mellbin

Affiliations

Soon will be listed here.

Abstract

Background: Increased risk of severe tachyarrhythmias is reported in patients with type 2 diabetes mellitus (T2DM). The aim of this study was to explore if treatment with cardiac implantable electronic device (CIED) such as implantable cardioverter defibrillator (ICD), cardiac resynchronization therapy- pacemaker and -defibrillator (CRT-P/CRT-D) differed in patients with vs. without T2DM. A secondary aim was to identify patient characteristics indicating an increased CIED treatment.

Method: 416 162 adult patients with T2DM from the Swedish National Diabetes Registry and 2 081 087 controls from the Swedish population, matched for age, sex and living area, were included between 1/1/1998 and 31/12/2012 and followed until 31/12/2013. They were compared regarding prevalence of ventricular tachycardia (VT) at baseline and the risk of receiving a CIED during follow-up. Multivariable Cox regression analysis was performed to estimate the risk of CIED-treatment and factors identifying patients with such risk.

Results: Ventricular fibrillation (VF) (0.1% vs 0.0004%) and (VT) (0.2% vs. 0.1%) were more frequent among patients with T2DM compared to controls. CIED-treatment was significantly increased in patients with T2DM both in unadjusted and adjusted analyses. HR and 95% CI, after adjustment for sex, age, marital status, income, education, country of birth, coronary artery disease and congestive heart failure, were 1.32 [1.21-1.45] for ICD, 1.74 [1.55-1.95] for CRT-P and 1.69 [1.43-1.99] for CRT-D. Blood-pressure and lipid lowering therapies were independent risk factors associated to receiving CIED, while female sex was protective.

Conclusions: Although the proportion of VT/VF was low, patients with T2DM had a higher prevalence of these conditions and increased risk for treatment with CIED compared to controls. This underlines the importance of recognizing that T2DM patients have an increased need of CIED.

References

Johansson I, Dahlstrom U, Edner M, Nasman P, Ryden L, Norhammar A . Type 2 diabetes and heart failure: Characteristics and prognosis in preserved, mid-range and reduced ventricular function. Diab Vasc Dis Res. 2018; 15(6):494-503. DOI: 10.1177/1479164118794619. View

Gregoratos G, Abrams J, Epstein A, Freedman R, Hayes D, Hlatky M . ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices: summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/NASPE.... J Cardiovasc Electrophysiol. 2002; 13(11):1183-99. DOI: 10.1046/j.1540-8167.2002.01183.x. View

Rawshani A, Rawshani A, Gudbjornsdottir S . Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes. N Engl J Med. 2017; 377(3):300-301. DOI: 10.1056/NEJMc1706292. View

Zinman B, Wanner C, Lachin J, Fitchett D, Bluhmki E, Hantel S . Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015; 373(22):2117-28. DOI: 10.1056/NEJMoa1504720. View

Curtis L, Al-Khatib S, Shea A, Hammill B, Hernandez A, Schulman K . Sex differences in the use of implantable cardioverter-defibrillators for primary and secondary prevention of sudden cardiac death. JAMA. 2007; 298(13):1517-24. DOI: 10.1001/jama.298.13.1517. View

Levey A, Stevens L, Schmid C, Zhang Y, Castro 3rd A, Feldman H . A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009; 150(9):604-12. PMC: 2763564. DOI: 10.7326/0003-4819-150-9-200905050-00006. View

Manuchehry A, Agusala K, Montevecchi M, Kadish A, Passman R . Ventricular tachyarrhythmias in patients receiving an implantable cardioverter-defibrillator for primary versus secondary prophylaxis indications. Pacing Clin Electrophysiol. 2011; 34(5):571-6. DOI: 10.1111/j.1540-8159.2010.03004.x. View

Nichols G, Gullion C, Koro C, Ephross S, Brown J . The incidence of congestive heart failure in type 2 diabetes: an update. Diabetes Care. 2004; 27(8):1879-84. DOI: 10.2337/diacare.27.8.1879. View

Chang S, Wu L, Chiou M, Liu J, Yu K, Kuo C . Association of metformin with lower atrial fibrillation risk among patients with type 2 diabetes mellitus: a population-based dynamic cohort and in vitro studies. Cardiovasc Diabetol. 2014; 13:123. PMC: 4149273. DOI: 10.1186/s12933-014-0123-x. View

10.

Ludvigsson J, Andersson E, Ekbom A, Feychting M, Kim J, Reuterwall C . External review and validation of the Swedish national inpatient register. BMC Public Health. 2011; 11:450. PMC: 3142234. DOI: 10.1186/1471-2458-11-450. View

11.

Ducceschi V, DAndrea A, Liccardo B, Sarubbi B, Ferrara L, Alfieri A . Perioperative correlates of malignant ventricular tachyarrhythmias complicating coronary surgery. Heart Vessels. 2000; 14(2):90-5. DOI: 10.1007/BF02481748. View

12.

Marx N, Federici M, Schutt K, Muller-Wieland D, Ajjan R, Antunes M . 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023; 44(39):4043-4140. DOI: 10.1093/eurheartj/ehad192. View

13.

Jouven X, Lemaitre R, Rea T, Sotoodehnia N, Empana J, Siscovick D . Diabetes, glucose level, and risk of sudden cardiac death. Eur Heart J. 2005; 26(20):2142-7. DOI: 10.1093/eurheartj/ehi376. View

14.

Cosentino F, Grant P, Aboyans V, Bailey C, Ceriello A, Delgado V . 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2019; 41(2):255-323. DOI: 10.1093/eurheartj/ehz486. View

15.

Jin X, Chandramouli C, Allocco B, Gong E, Lam C, Yan L . Women's Participation in Cardiovascular Clinical Trials From 2010 to 2017. Circulation. 2020; 141(7):540-548. DOI: 10.1161/CIRCULATIONAHA.119.043594. View

16.

Gudbjornsdottir S, Cederholm J, Nilsson P, Eliasson B . The National Diabetes Register in Sweden: an implementation of the St. Vincent Declaration for Quality Improvement in Diabetes Care. Diabetes Care. 2003; 26(4):1270-6. DOI: 10.2337/diacare.26.4.1270. View

17.

Weidner K, Behnes M, Schupp T, Rusnak J, Reiser L, Bollow A . Type 2 diabetes is independently associated with all-cause mortality secondary to ventricular tachyarrhythmias. Cardiovasc Diabetol. 2018; 17(1):125. PMC: 6130079. DOI: 10.1186/s12933-018-0768-y. View

18.

Marso S, Bain S, Consoli A, Eliaschewitz F, Jodar E, Leiter L . Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016; 375(19):1834-1844. DOI: 10.1056/NEJMoa1607141. View

19.

Tancredi M, Rosengren A, Svensson A, Kosiborod M, Pivodic A, Gudbjornsdottir S . Excess Mortality among Persons with Type 2 Diabetes. N Engl J Med. 2015; 373(18):1720-32. DOI: 10.1056/NEJMoa1504347. View

20.

Al-Khatib S, Stevenson W, Ackerman M, Bryant W, Callans D, Curtis A . 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and.... Heart Rhythm. 2017; 15(10):e73-e189. DOI: 10.1016/j.hrthm.2017.10.036. View